<SEC-DOCUMENT>0001628280-26-020375.txt : 20260323
<SEC-HEADER>0001628280-26-020375.hdr.sgml : 20260323
<ACCEPTANCE-DATETIME>20260323101009
ACCESSION NUMBER:		0001628280-26-020375
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260323
FILED AS OF DATE:		20260323
DATE AS OF CHANGE:		20260323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORGANIGRAM GLOBAL INC.
		CENTRAL INDEX KEY:			0001620737
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38885
		FILM NUMBER:		26780344

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		1400-145 KING ST. WEST
		CITY:			TORONTO
		PROVINCE COUNTRY:   	A6
		ZIP:			M5H 1J8
		BUSINESS PHONE:		506-232-4400

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		1400-145 KING ST. WEST
		CITY:			TORONTO
		PROVINCE COUNTRY:   	A6
		ZIP:			M5H 1J8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORGANIGRAM HOLDINGS INC.
		DATE OF NAME CHANGE:	20160831

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORGANIGRAM HOLDINGS INC
		DATE OF NAME CHANGE:	20140926
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kxmarch232026.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i28b2ed4bd7ca4b72b6b09e22d1d20ee2_1"></div><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Washington, D.C. 20549</font></div><div style="padding-left:216pt;padding-right:216pt;text-align:center"><font><br></font></div><div style="margin-top:7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">FORM 6-K</font></div><div style="padding-left:216pt;padding-right:216pt;text-align:center"><font><br></font></div><div style="margin-top:7pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the month of March 2026</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">001-38885</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">ORGANIGRAM GLOBAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:160%">145 King Street West, Suite 1400</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:160%;text-decoration:underline">Toronto, Ontario ,Canada M5H 1J8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Address of principal executive offices)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Form 20-F&#160;&#91;  &#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Form 40-F&#160;&#91; X &#93;</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">SUBMITTED HEREWITH</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Exhibits</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="pressreleasereissreport-ma.htm" style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">99.1</a></font></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Press release dated March 23, 2026</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">SIGNATURE</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:139%">ORGANIGRAM GLOBAL INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">&#47;s&#47; Greg Guyatt           </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">           </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Greg Guyatt</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Chief Financial Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Date&#58; March 23, 2026</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleasereissreport-ma.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if427ada0d0574c13b7e448e4e56b7865_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ISS Cites Compelling Strategic Rationale, Favorable Market Reaction, and Strong Institutional Confidence in Recommending Shareholders Vote FOR the Transaction Resolution</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TORONTO&#8212;(BUSINESS WIRE)&#8212;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 23, 2026 Organigram Global Inc. (NASDAQ&#58; OGI) (TSX&#58; OGI), (the &#8220;Company&#8221; or &#8220;Organigram&#8221;), a leading licensed producer of cannabis, is pleased to announce that Institutional Shareholder Services Inc. (&#34;ISS&#34;), a leading independent proxy advisory firm, has recommended that holders of common shares of Organigram (&#34;Shareholders&#34;) vote FOR the ordinary resolution (the &#34;Transaction Resolution&#34;) to approve the indirect acquisition of Sanity Group GmbH (&#34;Sanity&#34;) at the Company's Annual General and Special Meeting of Shareholders (the &#34;Meeting&#34;) to be held on Monday, March 30, 2026, at 10&#58;00 a.m. (Toronto time), at 333 Bay Street, Suite 3400, Toronto, Ontario.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those Shareholders who are unable to attend the Meeting in person, the Company will make an audio-only telephone conference available for Shareholders to listen to the Meeting. No voting will occur on the audio conference. To join the audio-only telephone conference, Shareholders can dial (646) 307-1963 (from Toronto) or (800) 715-9871 (toll-free) and quote the following reference number&#58; 96766. The registration URL for the audio-only telephone conference is https&#58;&#47;&#47;registrations.events&#47;direct&#47;Q4I967660.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its report dated March 14, 2026, ISS stated&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;padding-right:36pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;The strategic rationale for the deal makes sense and the combined company should be able to harness benefits from increased scale, diversification, improved market presence, a stronger balance sheet, and cash flow generation. The connected financing being done at a meaningful premium by OGI&#8217;s largest shareholder signal strong institutional confidence and long</font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8209;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">term strategic alignment. The valuation appears credible, and the company has outperformed broad global&#8230;benchmark indices since the unaffected date and the announcement, suggesting elevated non-approval risk.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In recommending that Shareholders vote FOR the Transaction Resolution, ISS specifically highlighted the following key factors&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Compelling Strategic Rationale&#58; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ISS concluded that the acquisition of Sanity positions the combined company to benefit from increased scale, meaningful geographic diversification, improved market presence, a stronger balance sheet, and enhanced cash flow generation.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Strong Institutional Confidence&#58; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The connected private placement financing by a wholly owned subsidiary of British American Tobacco p.l.c. (&#8220;BAT&#8221;), Organigram&#8217;s largest shareholder, completed at a meaningful premium to market price, was cited by ISS as a signal of strong institutional confidence and long-term strategic alignment with the transaction.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Credible Valuation&#58; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ISS found the valuation of Sanity to be credible, supported by an independent fairness opinion provided by BMO Nesbitt Burns Inc. confirming the consideration to be paid is fair, from a financial point of view, to Organigram.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Positive Market Reaction&#58; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ISS noted that OGI shares rose on the day of announcement and had further increased as at March 11, 2026, meaningfully outperforming both the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S&#38;P&#47;TSX Composite Index and the S&#38;P&#47;TSX Composite Pharmaceuticals Index over the same period. ISS indicated that this favorable market reaction suggests elevated risk if the transaction is not approved.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Unanimous Board Support&#58; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent members of Organigram&#8217;s Board of Directors unanimously approved the transaction (with the interested directors abstaining from voting), having weighed the risks and benefits of the transaction against the Company&#8217;s standalone alternatives.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the Proposed Acquisition</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Sanity shareholders will receive a combination of cash and Organigram shares, with a deemed value of C$3.00 per share, as consideration for all outstanding Sanity shares not already held by Organigram, representing a 71.4% premium to the closing price of Organigram&#8217;s Common Shares on the TSX on the last unaffected trading date prior to announcement. The total upfront consideration is &#8364;113.4 million (comprising &#8364;80.0 million in cash and &#8364;33.4 million in Organigram shares). In addition, Sanity shareholders are entitled to receive contingent earn-out consideration of up to &#8364;113.8 million tied to Sanity&#8217;s financial performance in the 12-month period following closing.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Recommendation and Other Meeting Matters</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors of Organigram unanimously (with the interested directors abstaining from voting) recommends that Shareholders vote FOR the Transaction Resolution. The Board consulted with its financial and legal advisors throughout the negotiation process and received a fairness opinion from BMO Nesbitt Burns Inc. confirming the fairness of the consideration paid under the share purchase agreement for the Transaction, from a financial point of view, to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Meeting, Shareholders will also be asked to vote on a number of other annual and special meeting matters, including&#58; the election of ten director nominees to the Board&#59; the appointment of PricewaterhouseCoopers LLP as the Company&#8217;s auditor&#59; and the re-approval of all  unallocated awards under the Company&#8217;s Omnibus Equity Incentive Plan. The Board recommends that Shareholders vote FOR each of the director nominees, FOR the appointment of PricewaterhouseCoopers LLP as auditor, and FOR the re-approval of all unallocated awards under the Company&#8217;s Omnibus Equity Incentive Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YOUR VOTE IS IMPORTANT</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders are encouraged to read the Management Information Circular dated February 23, 2026 (available on SEDAR+ at www.sedarplus.ca, on EDGAR at www.sec.gov.and on the Company&#8217;s website) carefully and to vote their shares as soon as possible, and in any event, prior to the voting deadline of 10&#58;00 a.m. (Toronto time) on Thursday, March 26, 2026.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders who have questions or need assistance with voting their shares should contact the Company&#8217;s proxy solicitation agent, Sodali &#38; Co, by telephone at 1-833-830-8205 (North America) or 1-289-695-3075 (outside North America), or by email at assistance&#64;investor.sodali.com.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Organigram Global Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cannabis-derived goods in Canada. Through its acquisition of Collective Project Limited, Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets. Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business partnerships to extend the Company's global footprint.  Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O&#8217; Buds, SHRED, SHRED&#8217;ems, Monjour, Tremblant Cannabis, Collective Project, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac Sup&#233;rieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario&#59; one in Aylmer and the other in London. The facility in Aylmer houses best-in class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).</font></div><div><font><br></font></div><div style="margin-bottom:18pt"><font style="background-color:#ffffff;color:#333333;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Sanity Group </font></div><div style="margin-bottom:18pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanity Group aims to improve people&#8217;s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. To harness the full potential of cannabis, Sanity Group invests in research of the cannabis plant and its active ingredients as well as in specific areas of application. Sanity Group, co-founded in Berlin in 2018 by Finn Age H&#228;nsel, includes Vayamed, avaay Medical and ZOIKS (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), vaay (lifestyle) and Grashaus Projects (recreational cannabis Swiss pilot project). Near Frankfurt am Main, Sanity Group also operates a logistics and production facility for cannabis pharmaceuticals. More information at sanitygroup.com&#47;press.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221; or variations of such words and phrases or state that certain actions, events, or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221; or &#8220;will&#8221; be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include changes to market conditions, consumer preferences and regulatory climate, and factors and risks as disclosed in the Circular, and the Company&#8217;s most recent annual information form, management&#8217;s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. Such assumptions include, without limitation, the receipt of the requisite approval of the Shareholders of the Transaction Resolution at the Meeting&#59; the receipt of all required regulatory approvals, including final approval of the TSX,&#59; the satisfaction or waiver of all conditions to closing of the Transaction&#59; the completion of the Transaction on the terms contemplated by the share purchase agreement dated February 18, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026 between the Company, Sanity and the shareholders of Sanity , the completion of the private placement financing with BAT on the terms contemplated by the subscription agreement dated February 18, 2026 between BAT and the Company&#59; and the realization of the anticipated benefits of the Transaction within the expected time periods. The forward-looking information included in this news release is provided as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR ORGANIGRAM INVESTOR RELATIONS ENQUIRIES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MAX SCHWARTZ </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director of Investor Relations </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investors&#64;organigram.ca</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
